{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"37"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"73"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"27"}],"units":"Participants"}],"description":"Determine percentage of patients with response at 8 cycles of treatment","groups":[{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG000","title":"Arm B (Ixazomib and Dexamethasone)"},{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO\n\nLenalidomide: Given PO","id":"OG001","title":"Arm C (Ixazomib, Dexamethasone, Lenalidomide)"},{"description":"UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG002","title":"Arm A (Ixazomib and Dexamethasone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At baseline and at 12 months","title":"Percentage of Patients With Response at Baseline and at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}